<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038308</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI8604</org_study_id>
    <secondary_id>1R21DK112093-01</secondary_id>
    <nct_id>NCT03038308</nct_id>
  </id_info>
  <brief_title>Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole</brief_title>
  <official_title>Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist
      ropinirole for the treatment of hyperprolactinemia in patients with idiopathic
      hyperprolactinemia and prolactinomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of prolactin secreting pituitary tumors with traditional ergot dopamine agonist
      drugs can be limited by medication side effects, pharmacologic resistance, and by concerns
      regarding the potential risk of cardiac valve disease. The overall goal of this project is
      therefore to evaluate, for the first time, the efficacy and tolerability of the selective
      D2/D3 receptor non-ergot dopamine agonist ropinirole for the treatment of prolactinomas. This
      proposal will establish the pharmacologic profile of this medication when used to treat
      hyperprolactinemia in patients with prolactinomas and will determine the impact of long-term
      ropinirole administration on critical clinical parameters including serum prolactin levels,
      gonadal function, and tumor regression, in order to establish ropinirole's utility as a new,
      clinically efficacious, safer and more tolerable therapeutic option for the treatment of
      prolactinomas that may prove particularly useful in patients with underlying cardiac valve
      disease and in those with resistance or intolerance to ergot dopamine agonists.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>1) Forced titration dose response PKPD study and 2) A prospective open-label outpatient dose escalation trial of ropinirole for treatment of prolactinomas and hyperprolactinemia.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label studies</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prolactin concentrations</measure>
    <time_frame>6-12 months</time_frame>
    <description>Serum prolactin concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor size</measure>
    <time_frame>6-12 months</time_frame>
    <description>Radiologic assessment of tumor size before and after treatment will be made by MRI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Hyperprolactinemia</condition>
  <condition>Prolactinoma</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole</intervention_name>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-70 years

          -  Prolactin level (PRL) ≥2 times upper limit of normal

          -  Pituitary adenomas on MRI ≤ 1.5cm in greatest diameter and ≥ 5mm from the optic chiasm

          -  Normal renal and liver function

          -  Agrees to barrier contraception if pre-menopausal

        Exclusion Criteria:

          -  Use of medications known to interfere with PRL secretion and PRL and Ropinirole (ROP)
             metabolism

          -  Use of another dopamine agonist during the 4 weeks prior

          -  Pituitary stalk compression on MRI

          -  History of visual field abnormalities or previous radiation

          -  Untreated hypothyroidism

          -  Consumption of &gt; 2 alcoholic drinks per day

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabrielle Page-Wilson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabrielle Page-Wilson, M.D.</last_name>
    <phone>212-305-3725</phone>
    <email>gp2287@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Page-Wilson, M.D.</last_name>
      <phone>212-305-3725</phone>
      <email>gp2287@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gabrielle Page-Wilson</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>ropinirole</keyword>
  <keyword>hyperprolactinemia</keyword>
  <keyword>prolactin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Prolactinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

